Ohio State University Comprehensive Cancer Center

James Cancer Hospital and Solove Research Institute

Columbus, OH

Sorting 14 by

Accepting patients

QUINTESSENTIAL

Phase 2 Study of BMS-986393, a GPRC5D-directed CART-Cell Therapy, in Participants with Relapsed or Refractory Multiple Myeloma
  • CAR T Cell
  • GPRC5D
  • Phase 2

Accepting patients

DREAMM-10

Phase 3 Clinical Trial Comparing the Safety and Efficacy of Belantamab Mafodotin, Lenalidomide and Dexamethasone Versus Daratumumab, Lenalidomide and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma who are Ineligible for Autologous Stem Cell Transplant
  • Antibody Drug Conjugate (ADC)
  • BCMA
  • Phase 3

Accepting patients

MajesTEC-7

A Study to Compare Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) in Participants With Newly Diagnosed Multiple Myeloma (MajesTEC-7)
  • Bispecific Antibody
  • BCMA
  • Randomization
  • Phase 3
  • Has results

Accepting patients

Sonrotoclax (BGB-11417)

A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
  • BCL-2 Inhibitor
  • Phase 1/2
  • Has results

Accepting patients

Linvoseltamab

A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
  • Bispecific Antibody
  • BCMA
  • Phase 1
  • Has results

Accepting patients

Isatuximab in Combination With Novel Agents

Phase 1-2 UMBRELLA Trial Evaluating Isatuximab With or Without Dexamethasone in Combination With Novel Agents Compared to Isatuximab With Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma (RRMM) - Master Protocol
  • Monoclonal Antibody
  • CD38
  • Randomization
  • Phase 1/2

Accepting patients

LP-118

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory NHL, RT, MM, T-PLL, Acute Leukemia (AML, ALL), MDS, MDS/MPN, and MF
  • BCL-2 Inhibitor
  • Bcl/xL Inhibitor
  • Phase 1

Accepting patients

Isatuximab in Frail Patients

Isatuximab Plus Lenalidomide and Dexamethasone for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
  • Monoclonal Antibody
  • CD38
  • Phase 2

Accepting patients

Tissue Banking

Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample Resource
  • Observational Trial

Accepting patients

TECVAYLI

A Phase 1b Trial of Teclistamab in Combination With Iberdomide for Relapsed/Refractory Multiple Myeloma
  • CELMoD
  • Bispecific Antibody
  • BCMA
  • Phase 1
2 hidden based on your filters.Show All